Who's doing what on EMA call for generics suspension after Indian CRO data manipulation
This article was originally published in SRA
Executive Summary
The European Commission says that "within roughly a month" it will make its decision on the European Medicines Agency's recommendation that hundreds of formulations and strengths of generic medicines whose European marketing authorizations relied on clinical studies performed by Indian contract research organization GVK Biosciences be suspended in the EU1.
You may also be interested in...
India Global Trial Hub Dreams Still Distant As Concerns Linger
Indian clinical trial approvals appear to be on the downswing despite government moves to boost the troubled sector, as regulatory uncertainty and negative publicity continue to undermine confidence in the industry.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.